Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli-Reference-Cited by-同舟云学术

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

Published:2017-06-07 Issue:1 Volume:17 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Seo Yu Bin,Lee Jacob,Kim Young Keun,Lee Seung Soon,Lee Jeong-a,Kim Hyo Youl,Uh Young,Kim Han-Sung,Song Wonkeun

Funder

Ministry of Health & Welfare, Republic of Korea

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-017-2502-x.pdf

Reference41 articles.

1. Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-Spectrum beta-Lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol. 2016;37(1):49–54.

2. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5):2137–9.

3. Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006;50(8):2695–9.

4. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006;42(Suppl 4):S164–72.

5. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–86.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of early use of Carbapenems perioperatively for urolithiasis with ESBL-producing Escherichia coli;BMC Urology;2024-09-06

2. Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia;European Journal of Clinical Microbiology & Infectious Diseases;2024-07-17

3. Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing;Clinical Infectious Diseases;2024-06-21

4. A targeted likelihood estimation comparing cefepime and piperacillin/tazobactam in critically ill patients with community-acquired pneumonia (CAP);Scientific Reports;2024-06-11

5. Beta-lactam antibiotic resistance among Escherichia coli isolates from patients with urinary tract infections in Vietnam: A systematic review and meta-analysis;Asian Pacific Journal of Tropical Medicine;2024-06